Register Now
Why register?
 The leading web portal for pharmacy resources, news, education and careers November 21, 2017
Pharmacy Choice - Pharmaceutical News - Bio Farma Set on Launching More Affordable Breast Cancer Drug by 2019 [Sudan Tribune] - November 21, 2017

Pharmacy News Article

 3/20/17 - Bio Farma Set on Launching More Affordable Breast Cancer Drug by 2019 [Sudan Tribune]

Bio Farma plans to launch a biosimilar drug specifically for breast cancer that is more affordable by 2019.

Bio Farma senior researcher Erman Tritama said in Bandung on Sunday (3/19) the research and development team have created a biosimilar medicine that is ready to be launched and sold by 2019.

Erman said Bio Farma plans to sell the biosimilarbiological products derived from living organisms such as tissues, cells, DNA, and proteinsdrug with prices that are more than 50% lower than the biosimilar breast cancer drug produced by European company Roche, which is worth IDR25 million in one dose.

"The breast cancer biosimiar drug is patented for 20 years, and the patent will expire in 2019," said Erman.

The patent had caused other companies to not be allowed to create biosimilar drugs, and the company owning the patent could monopolize the price by selling at high prices.

Biosimilar for breast cancer with active ingredient "trastuzumab" is used to streamline chemotherapy to lessen the side effects and accelerate healing process. Patients need to use biosimilar at least five times. In other words, breast cancer patients have to spend IDR125 million to buy the biosimilar medicine.

However, Bio Farma is a State-Owned Enterprise (SOE) with a mission to seek treatment at an affordable price, especially for the people of Indonesia.

"We plan on selling the drug at 30% of its current price, or at around IDR7.5 million, Erman said.

Thus, the total cost buying biosimilar drug will drop to IDR37.5 million from IDR125 million.

Erman said Indonesia should be prepared as soon as possible and launch a biosimilar product for breast cancer so that other companies do not sell the drugs with more expensive price. "The patent will expire in 2019. Other companies in other countries have also been preparing to launch their products. We have to hurry, and only compete with the cheap price," he said.

The advantage of biosimilar drugs over chemical drugs is that biosimilar drugs have fewer side effects and are easily digested by the body because its base is made of molecules of living beings.

Bio Farma is also developing vaccines for typhoid and diseases of the lungs (pneumonia), which is much cheaper than the market price in order to improve the quality of life in Indonesia.

(c) 2003-2017 SudanTribune - All rights reserved. Provided by SyndiGate Media Inc. (

Pharmacy News Index
  Drug Delivery Systems
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry


Last Chance
Nov 21: Standards of Practice for Filling Controlled Substance Prescriptions in Florida
Last Chance
Nov 22: Medical Marijuana: Examining the Science, Not the Politics
Nov 27: Drug Diversion and the Law: Updates and Considerations
Nov 28: An Integrative Approach to Managing Arthritis
Nov 29: Influenza 2017-2018: An Update on Prevention and Treatment
Click for entire Webinar Calendar

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...

Nursing Jobs
Are you a nurse looking for a job?

Check out the Nursing Job Source.

Your number one choice for nursing jobs.

Websites »
Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement